These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9490358)

  • 1. [Kinetic drug Motilium: pharmacological properties and potential clinical use].
    Sheptulin AA
    Klin Med (Mosk); 1997; 75(11):48-50. PubMed ID: 9490358
    [No Abstract]   [Full Text] [Related]  

  • 2. Making a case for domperidone in the treatment of gastrointestinal motility disorders.
    Ahmad N; Keith-Ferris J; Gooden E; Abell T
    Curr Opin Pharmacol; 2006 Dec; 6(6):571-6. PubMed ID: 16997628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage and drug interactions of domperidone.
    Robinson P
    Am J Gastroenterol; 2008 Apr; 103(4):1049. PubMed ID: 18397438
    [No Abstract]   [Full Text] [Related]  

  • 4. Domperidone: review of pharmacology and clinical applications in gastroenterology.
    Reddymasu SC; Soykan I; McCallum RW
    Am J Gastroenterol; 2007 Sep; 102(9):2036-45. PubMed ID: 17488253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential pharmacological approaches to management of gut motility disorders.
    Malagelada JR
    Scand J Gastroenterol Suppl; 1984; 96():111-26. PubMed ID: 6382573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Domperidone affects the interdigestive motility in the jejunum (author's transl)].
    Richter A; Erckenbrecht J; Wienbeck M
    Z Gastroenterol; 1981 Dec; 19(12):767-71. PubMed ID: 7034388
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of dopamine D2 receptor antagonists on gastrointestinal motility].
    Mizumoto A; Ito A
    Nihon Heikatsukin Gakkai Zasshi; 1990 Apr; 26(2):65-9. PubMed ID: 2273688
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of the prokinetic domperidine in patients in the early postoperative period].
    Aleksseva EV; Fominykh VP; Tropskaia NS; Popova TS
    Khirurgiia (Mosk); 2010; (3):62-9. PubMed ID: 20517269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of prokinetic drugs inhibiting dopaminergic system on gallbladder motility in subjects with duodenal ulcer].
    Szabelska K; Chojnacki J; Grzegorczyk K; Mamos A
    Pol Merkur Lekarski; 1999 Apr; 6(34):188-91. PubMed ID: 10391057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Motility-effective drugs for therapy of gastrointestinal functional disorders].
    Weihrauch TR; Kilbinger H
    Dtsch Med Wochenschr; 1982 Sep; 107(35):1323-8. PubMed ID: 6749465
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
    Seeman P; Tallerico T; Ko F
    Synapse; 2003 Sep; 49(4):209-15. PubMed ID: 12827639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of a new gastrokinetic drug on gastrointestinal motility: domperidone, a peripheral antidopaminergic drug].
    Chevrel B
    Med Chir Dig; 1981; 10(2):175-8. PubMed ID: 7230953
    [No Abstract]   [Full Text] [Related]  

  • 13. [What is assured in therapy of gastrointestinal diseases with drugs acting on motility?].
    Müller-Lissner S; Klauser A
    Internist (Berl); 1989 Dec; 30(12):797-804. PubMed ID: 2695489
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of Motilium with gastrokinetic and anti-emetic action in outpatients.
    Porkoláb E
    Ther Hung; 1988; 36(3):132-5. PubMed ID: 3250001
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
    Miyazawa T; Matsumoto M; Kato S; Takeuchi K
    Med Sci Monit; 2003 Feb; 9(2):BR71-7. PubMed ID: 12601282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MODERN PROKINETICS AND THEIR ROLE IN THE TREATMENT OF GASTROENTEROLOGICAL PATHOLOGY].
    Sheptulin AA; Belousova IB
    Klin Med (Mosk); 2016; 94(3):178-82. PubMed ID: 27522721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diseases of gastrointestinal motility. Treatment with motility-modifying substances].
    Storr M; Allescher HD
    Med Monatsschr Pharm; 2003 Aug; 26(8):260-9. PubMed ID: 12953379
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gastrointestinal motility disorders and drugs: cholinergic, anticholinergic, adrenergic, antiadrenergic and prokinetic drugs (part I)].
    Jovanović-Mićić D; Janković S; Beleslin DB
    Srp Arh Celok Lek; 1994; 122(1-2):50-4. PubMed ID: 17972806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical pharmacology and therapeutic results of a specific antagonist in disorders of gastroduodenal and peripheral motility].
    Bertrand J; Thillier JL
    Sem Hop; 1980 Oct 18-25; 56(39-40):1579-81. PubMed ID: 6255572
    [No Abstract]   [Full Text] [Related]  

  • 20. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.